372 related articles for article (PubMed ID: 37275877)
61. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
[TBL] [Abstract][Full Text] [Related]
62. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
[TBL] [Abstract][Full Text] [Related]
63. Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.
Forlenza CJ; Rosenzweig J; Mauguen A; Buhtoiarov I; Cuglievan B; Dave H; Deyell RJ; Flerlage JE; Franklin AK; Krajewski J; Leger KJ; Marks LJ; Norris RE; Pacheco M; Willen F; Yan AP; Harker-Murray PD; Giulino-Roth L
Blood Adv; 2023 Jul; 7(13):3225-3231. PubMed ID: 36897253
[TBL] [Abstract][Full Text] [Related]
64. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Ramchandren R; Bartlett NL; Cheson BD; de Vos S; Forero-Torres A; Moskowitz CH; Connors JM; Engert A; Larsen EK; Kennedy DA; Sievers EL; Chen R
J Clin Oncol; 2012 Jun; 30(18):2183-9. PubMed ID: 22454421
[TBL] [Abstract][Full Text] [Related]
65. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.
Gibb A; Jones C; Bloor A; Kulkarni S; Illidge T; Linton K; Radford J
Haematologica; 2013 Apr; 98(4):611-4. PubMed ID: 23065511
[TBL] [Abstract][Full Text] [Related]
66. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
67. Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin.
Sasapu A; Dunn ALJ; Gardner J; Wong HK
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290015
[TBL] [Abstract][Full Text] [Related]
68. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
[TBL] [Abstract][Full Text] [Related]
69. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
[TBL] [Abstract][Full Text] [Related]
70. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
71. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
72. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
73. Brentuximab vedotin.
Drugs R D; 2011; 11(1):85-95. PubMed ID: 21410298
[TBL] [Abstract][Full Text] [Related]
74. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
[TBL] [Abstract][Full Text] [Related]
75. [ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin].
Arai H; Furuichi S; Nakamura Y; Nakamura Y; Ichikawa M; Mitani K
Rinsho Ketsueki; 2016 May; 57(5):634-7. PubMed ID: 27263791
[TBL] [Abstract][Full Text] [Related]
76. CD30-targeted antibody therapy.
Younes A
Curr Opin Oncol; 2011 Nov; 23(6):587-93. PubMed ID: 21986847
[TBL] [Abstract][Full Text] [Related]
77. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
78. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
79. Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin.
Veleanu L; Lamant L; Sibon D;
N Engl J Med; 2024 Jun; 390(22):2129-2130. PubMed ID: 38865667
[No Abstract] [Full Text] [Related]
80. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
Goyal SD; Bartlett NL
Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]